What is BrachyDOSE?
BrachyDOSE is developing a critical quality control tool designed to enhance the precision of radiotherapy treatments for oncologists. The company addresses the challenge of verifying accurate radiation dosage delivery to tumors while safeguarding surrounding healthy organs, thereby mitigating risks of radiation burns and secondary illnesses. Their proposed solution involves a system comprising a radiation dose measurement tool (dosimeter) and a reader, differentiating itself from dose simulation applications by providing accurate, science-based data. BrachyDOSE's system is noted for its ease of use and high compatibility with standard medical devices. The company's expertise is built upon over seven years of research in radiation-sensitive materials and device engineering, complemented by extensive project leadership and scientific research experience, including collaborations with the Lithuanian Health Science University Kaunas Clinics and the National Cancer Institute (Lithuania).
How much funding has BrachyDOSE raised?
BrachyDOSE has raised a total of $641K across 1 funding round:
Seed
$641K
Seed (2025): $641K with participation from BSV Ventures, Lithuanian Business Angel Network, Estonian Business Angels Network ESTBAN, and Coinvest Capital
Key Investors in BrachyDOSE
BSV Ventures
BSV Ventures is an early-stage venture capital firm focused on Deep Tech, Life Science, and Dual-Use Tech, particularly in the Baltic region, supporting R&D-driven teams with significant commercial potential.
Lithuanian Business Angel Network
LitBAN is a community of angel investors providing financial resources and expertise to early-stage companies with high growth potential, fostering the Lithuanian startup ecosystem.
Estonian Business Angels Network ESTBAN
EstBAN is a member-led organization that connects investors with quality deal flow and supports startups with capital and mentorship, facilitating syndicated investment rounds.
What's next for BrachyDOSE?
The recent major strategic investment signals a pivotal growth phase for BrachyDOSE, likely enabling the company to scale its operations, further refine its technology, and expand its market reach. This capital infusion is expected to accelerate the development and commercialization of their innovative brachytherapy quality control system, positioning BrachyDOSE to become a key player in improving cancer treatment outcomes globally. The company's focus on providing empirical, measurement-based proof of radiation dosage, rather than relying solely on simulations, provides a distinct competitive advantage in a market prioritizing accuracy and patient safety.
See full BrachyDOSE company page
